SlideShare a Scribd company logo
1 of 46
ARE JAK 2 INHIBITORS THE SOLUTION
FOR TREATMENT OF
MYELOPROLIFERATIVE DISEASES
DONE BY:
TAMMALI HARIKA (09Z31R0020)
AINALA SRAVANI REDDY (09Z31R0024)
KUTHADI PRIYANKA (09Z31R0042)
MAILARAPU NAVYA (09Z31R0045)
MUTHYAM ROJA RANI (09Z31R0046)
SAFURA AYESHA MUJEEB (09Z31R0054)
UNDER THE GUIDANCE OF
MRS . SIVA JYOTHI BUGGANA,
M. PHARMACY
MEDICINAL CHEMISTRY
CONTENTS.
• Abstract
• Introduction to cancer
• Targets of Cancer
• Plan of work
• Introduction to Janus Kinases (JAK)
• Introduction to STAT
• Coordination between JAK and STAT
• Scaffolds used to synthesize JAK2 inhibitors
• JAK2 inhibitors under clinical phases
• Conclusion
• Bibliography
• ABSTRACT:
• Janus kinases (JAKS) are critical components of cytokine signaling
pathways which regulate immunity, inflammation, haematopoiesis,
growth and development.
• The recent discovery of JAK2- activating mutations as a casual event in
majority of patients with Philadelphia chromosomes negative (ph-
)myeloproliferative disorders (MPDS) promoted many pharmaceutical
companies to develop JAK2 selective inhibitors for the treatment of
MPD’S
• JAK2 inhibitors effectively reduce JAK2 driver phosphorylation of signal –
transducer and activator of transcription 5, and cell survival in JAK 2
activated cells in vitro and invivo.
• Patients treated with these inhibitors experience a rapid reduction of
splenomegaly, significant improvement of constitutional symptoms.
INTRODUCTION:
• Cancer is a disease in which there is uncontrolled multiplication
and spread within the body of abnormal forms of the body’s own
cells.
• They are distinguished from benign tumours by the properties of
dedifferentiation, invasiveness and the ability to metastasise (spread
to other parts of the body) both benign and malignant tumours
manifest uncontrolled proliferation.
• PATHOGENISIS OF CANCER:-
• Cancer cell distinguish from normal cell by :-
• 1. Uncontrolled proliferation
• 2. Dedifferentiation
• 3. Invasiveness
• 4. Metastasis.
APOPTOSIS
• Apoptosis is programmed cell death . Development of resistance to
apoptosis is hallmark of cancer. The decrease of apoptosis can be
brought about inactivation of proapoptotic factors or by activation of
antiapoptotic factors
GENESIS OF A CANCER CELL:-
A normal cell turns into a cancer cell because
of one or more mutations in its DNA which can
be inherited or acquired.
There are two main categories of genetic change
that lead to cancer they are :
1)Activation of proto oncogenes to oncogenes .
2)Inactivation of tumour suppressor genes.
Eg: breast cancer.
CELL CYCLE:-
The normal cell proliferate throught a definite cell cycle that causes
programme DNA replications.
The mechanism of cell division is same in all dividing phase and is divided
into 5 phases.
They are:
1. Go(Gap o (or) Resting (or) non-Proliferative phase)
2. Phase G1
3. S Phase
4. G2 Phase
5. M-Phase
NEGATIVE REGULATORS OF CELL CYCLE:-
• Rb protein that holds the cycle in check while it is hypophosphorylated
another negative regulatory mechanism is the action of the inhibitors of
the cdk’s.
• These bind to and inhibits the action of the complexes, their main actions
being at check point 1.
THERE ARE 2 FAMILIES OF INHIBITORS:-
1) Kinase inhibitory protein family (cdk inhibitory proteins, also termed
KIP/kinanes inhibitory proteins:P21,P27 and P53.
2) Inhibitors of kinase family (INK FAMILY):- P16, P19, P15.
TARGET SITES
• A) CONVENTIONAL OR TRADITIONAL TARGETS:
• These include alkylating agents, anti metabolites, antibiotics, plant
alkaloids, radio isotopes.
• B) NEXT GENERATION TARGETS:
• 1. Cell signaling pathway
• 2. Protein therapy
• 3. Protein- protein interaction
• Cancer related genes as targets:
• These genes are of 2 types they are:
• a)oncogenes. b) Tumour suppressor gene.
1.Oncogenes:
oncogenes contribute to the transformation process by driving cell
proliferation or reducing sensitivity to cell death.
Classes of oncogenes-
a)Growth factors: GF’S are produced by one cell and they act on other cells
this is known as paracrine stimulation. Cancer cell secrete their own GF’S
and they proliferate to form tumours this is known as autocrine
stimulation.
b)Growth factor receptors
c)Membrane associated guanine nucleotide binding protein.
d)Serine threonine protein kinases.
e)Cytoplasmic proteins.
f)Cytoplasmic tyrosine kinases.
2.Tumour suppressor genes:
These genes can directly or indirectly inhibit cell growth.
Direct inhibitors promote cell death and are called `gate keepers’ and
their activating is rate limiting for tumor cell proliferation. Indirect
inhibitors promote genetic stability and are called `care takers’ which
function in DNA repair pathways and whose elimination causes
increased initiation rate.
a)Retinoblastoma : Loss of Rb protein function leads to malignancy. It may
be either phosphorylated or unphosphorylated.
b)p53: it is activated in respose to cellular stresses created by activated
oncogenes.
Biochemical targets:
a)Reactive oxygen species- Ionizing radiation is the complete carcinogen and
causes DNA damage.
b)Matrix metalloproteinases -They play an integral role in malignant
progression.
c)Telomerase expression-Telomers are specialised structures that cap the ends
of chromosomes (like small metal tubes on the end of shoe lace)
protection them from the degradation, rearrangement and fusion with
other chromosomes. A portion of telomere is eroded with each round of
cell division so that eventually it becomes non functional
PLAN OF WORK
• Till now anticancer drugs available in the market are almost having
same mechanism of action, that is damaging the DNA synthesis in
affected cells and also damaging the normal cells along with the
neoplastic cells.
• Now we are trying to collect the information regarding the
treatment of cancer by using future generation targets, one of that is
Janus kinase inhibitors. Here we are ready to present the information
regarding Janus kinases.
INTRODUCTION:-
 JAK2V617F was the first mutation to be described in patients with ph-
negative MPN’S and the fact that it can be detected in patients with all 3
classic subtypes of MPN’s.
 After discovery of JAK2V617F;other investigators discovered mutation
in related genes of hemopoietic growth factor signaling
pathways,including exon 12 mutations in JAK2,Mutation of MPL.
THE JAK FAMILY OF TYROSINE KINASE:
• The JAK family of tyrosine kinase (named after the two faced roman god
janus) was first described in 1989.
• There are four members of the JAK family ; JAK1,JAK2,JAK3 and TYK.
• JAKs are cytoplasmic kinases that associate with the intracellular portion
of cytokine receptors that do not posses intrinsic kinase activity ,such as
receptors for hematopoietic growth factors (erythropoietin receptor [EPOR]
,G-CSF receptor [G-CSFR] ,and thrombopoietin receptor [C-MPL]
• Binding of the putative ligand leads to receptor dimerization and
subsequent approximation of two JAK kinases ,which transphosphorylates
and activate each other, initiating intracellular signalling pathways
• One of the most important intracellular signalling pathways activated by
JAKs is the JAK-STAT(signal transducer and activator of transcription)
pathway.
• STAT are latent,cytoplasmic transcription factors. JAKS phosphorylate
STATs tyrosine residues; leading to STAT dimerization , translocation to
the nucleus and activation of transcription.
• Aberrant activation of STAT3 and STAT5 has been linked to neoplastic
transformation.
• Other signalling pathways which can be activated by ;JAKs include the
Ras/Raf/MAPK pathway and the PBK/Akt pathway. Activation of these
pathways leads to increased cellular proliferation and resistance to
apoptosis , and deregulation could cause the development hematological
malignancies.
• Structurally,JAKs consists of seven different domains
THE JAK 2 V617F MUTATION:-
• It was identified primarily in patients with PV (90-97%), ET (60%) and
PMF (50%).
• It was identified primarily in patients with PV (90-97%), ET (60%) and
PMF (50%).
• In PV > 75% allelic burden is associated with higher hematocrit, white
blood cell (WBC) count, and higher incidence splenomegaly and
thrombotic events. Patients with primary MF who are JAk 2 V617F –
positive may have higher haemoglobin & WBC count and a higher risk of
leukemic transformation & of developing massive splenomegaly . V617F
appears to promote a polycythaemic phenotype in patients with both ET &
IMF
• The patients with V617F – negative MPNS led to the discovery of other
mutation JAk 2 exon 12 mutation in 3% of pv patients.
• These mutations also lead to increased cellular proliferation and hyper
sensitivity or independency to hematopoietic growth factors indeed, JAK 2
V617F negative erythroid colonies from patients with PV can grow in the
absence of erythropoietin.
RATIONALE FOR TARGETING JAK 2 IN MPN’S :
• Imatinib, These drugs target kinases that are abnormally activated in
cancer cells, with the objective of blocking cellular proliferation and
inducing apoptosis .
There is great therapeutic benefit for employing these drugs to achieve
symptom control and improve the quality of life of patient with MPNS
SCAFFOLDS USED AS JAK-2 INHIBITORS:
QUINAZOLINES 2,4-diamino triazole.
QUINOXALINES 3,4-ring fused 7-
azaindoles
Pyrazole-3-ylamino pyrazines Thienopyridines
Pyrazolo[1,5-a] pyrimidines 2-thio-benzoxazoles
JAK2 INHIBITORS UNDER CLINICAL TRIALS
1. CEP-701: It is also known as a lestaurtinib is a TK1 which belongs to the
chemical class of indocarbazol of alkaloid. It is a potent FLT3 and JAK2
inhibitor.
• DOSE: 80-100mg twice daily as a liquid formulation.
• USES:
 Reduction in spleen size with improvement in cytopenias.
 Use to treat patients with JAK2V617F-positive primary MF (or) post
PV/ET MF and clinical .
• ADRS:
* Myelosuppression.
*GI toxicity
2. AZD1480: it is a pyrazolyl pyrimidine compound that selectively and
potently inhibits JAK2.
• MOA: This compound block STAT 5 activation, inhibit the cell
proliferation and induced apoptosis in the human JAK2V617F positive.
• In a mouse model, AZD-1480 reduced the proliferation of stem cells
transferred with the JAK2 mutant protein.
• USES:
 Therapy with AZD 1480 inhibited tumour growth, and tumour cells
lysates had reduced level phospho STAT3.
 A phase 1 clinical trail is currently underway to evaluate the activity of
AZD1480 in patients with MPNS.
3.R723: This compound is strongly antiproliferative against mouse and
human cell lines that harvor the JAK2V617F mutation , constitutive
STAT5 phosphorylation in JAK2V617F positive cells was inhibited 10-20
fold more potently than IL-2 induced STAT5 phosphorylation
4. XL019: It is a potent , reversible and selective inhibitor of both wild
type and mutated JAK2 and shows good selectivity for JAK2 invitro
biochemical assays.
DOSE: Given orally once daily or three times weekly.
Tolerated dose is 25 and 50mg/kg.
ADRS:
* Non-haematological adverse effects.
* Leukocynosis, decrease of circulating blasts, improvement of anaemias,
pruritis and poor appetite.
5. INCB018424: It is a potent pan JAK inhibitor targeting JAK1,
JAK2,and TYK2.
• MOA:INCB018424 Inhibits constitutive and IL-6 stimulated
phosphorylation of STAT3 and reduces production of proinflammatory
cytokines in all MF patients regardless of their JAK2 mutation status.
• DOSE: The starting dose of 25mg pobid was demonstrated to be
maximum tolerated dose.
• USES:
 Therapy with INCB018424 also improved hyper catabolism-associated
hypocholestrolemia.
 INCB018424 treatment also resulted in a rapid reduction of spleenomegaly.
INCB-18424
• 6. SB1518: It is a JAK2 inhibitor that has activity against both wild
type and mutated JAK2,being selective against JAK1 and JAK3.
• MOA: SB1518 INHIBITS PROLIFERATION OF Baf/3 cells
transferred with the erythropoietin receptor (EPOR) and the JAK2
V617F mutation and decreased phosphorylation of JAK2 and STAT5.
• DOSE: Ranged from 100- 600mg orally once daily in 28-days cycles.
• ADRS:
 Abdominal pain and diarrhea.
 Nausea and thrombocytopenia.
7. TG101348:It is an orally available, potent JAK2 inhibitor with greater
selectivity against JAK1 and JAK3.
. USES:
• TG101348 is able to induce response in splenomegaly in the majority of
patient with MF and this may be due to a direct effect on inhibition of
JAK2V612F.
• MOA:TG101348 inhibited proliferation and induce apoptosis of JAK2
V617F positive HEL cells and Ba/f3 cells transduced with JAK V617F.
Dose: TG101348 was well tolerated in patience with MF when the drug was
taken orally once a day.
ADRS:
Non hematological toxicities.
Thrombocytopenia, neutropenia, Tronuition depended anaemia.
• TG101348 also led to improvement in system is symptoms, including
pruritis, night sweats, fatigue
• 8. CYT387:It is a amino pyrimidine compound is an ATP competitive
small molecules that potently inhibits JAK1 and JAK2 . CYT387 also
inhibits JAK3 but to a lesser extent.
MOA:CYT387 inhibits proliferation of
cell lines that depend on signaling by
JAK kinases for proliferation, including
Ba/f3 cells engineered to express both
EPOR and JAK2 V617F .
• USES:
 Therapy with CYT387 in mice developed with the splenomegaly ,
erythrocytosis , leukocytosis , splenomegaly and bone marrow fibrosis
improved hemoglobin levels , normalized WBC counts and reduced spleen
size.
 A reduction but not elimination of JAK2 disease burden , with partial
normalization of progenitor cell distribution and differentiation by this
compound was also observed in the model.
• DRUGS UNDER CLINICAL TRIALS
•
DRUG CURRENT PHASE
CEP701 ‫װ/׀‬
AZD1480 ‫׀‬
R723 Pre-clinical
XL019 ‫׀‬
INCB18424 ‫׀׀׀‬
SB1518 ‫׀‬
TG101348 ‫װ‬
CYT387 ‫׀‬
Conclusion
• Jak 2 inhibitors are a new class of drugs being actively developed for
patients with ph negative MPNs they are the solution to all clinical
issues in patients with MPNs, great clinical benefit can be obtained by
the use of these drugs.
• In patients with MF, therapy JAK2 inhibitors can lead to improvement
in spleen size, WBC count weight loss, fatigue, night sweats and is
associated with improved quality of life.
BIBILOGRAPHY:-
1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the
tyrosine Kinase JAK 2 in human myeloproliferative disorders, Lancet 2005;
365: 1054-61.
2. James C; Ugo V, Le Couedic JP et al. A unique clonal JAK 2 mutation
leading to constitutive Signaling causes polycythaemia Vera, Nature
2005; 434: 1144-8.
3. Kralovics R, passamonti F, Buser AS, et al; A gain of function mutation
of JAK 2 in myeloproliferative disorders N Engl Med 2005; 352: 1779-90.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the
tyrosine kinase JAK 2 in polycythemia vera, essential thrombocythemia
and myeloid metaplasia with myelofibrosis, Cancer cell, 2005; 7: 387-97.
• 5. Akada H, Yan D, Zou H, et al. conditional expression of heterozygous
(or) homozygous JAK 2 V 617 F from its endogenous promoter
induces a polycythemia Vera like disease Blood 2010; 115: 3589-97.6.
Bumm TG; Elsea C,
• 6. Bumm TG; Elsea C, Corbin AS, et al. characterization of murine JAK 2
V 617F-positive myeloproliferative disease Cancer Res 2006; 66: 11156-65.
• 7. Lacout C, pisani DF, Tulliez M, et al. JAK 2 V 617 F expression in
murine hematopoietic cells leads to MPD mimicking human pv with
secondary myelofibrosis, blood 2006; 108: 1652-60.
• 8. LiJ, Spensberger D, Ahn JS, et al, JAK 2 V 617 F impairs hematopoietic
stem cell function in a conditional Knock-in mouse model of JAK 2 V 617
F-positive essential thrombocythemia, Blood 2010; 116: 1528-38.
• 9. Marty C, Lacout C, Martin A, et al. myeloproliferative neoplasm
induced by constitutive expression of JAK 2 V 617 F in Knock-in mice,
Blood 2010; 116; 783-7.
• 10. Mullally A, Lane SW, Ball B, et al. physiological JAK 2 V 617 F
expression causes a lethal myeloproliferative neoplasm with differential
effects on hematopoietic stem and progenitor cells. Cancer cell 2010;
17:584-96.
• 11. Shide K; Shimoda HK; Kumano T, et al. Development of ET,
primary myelofibrosis and pv in mice expressing JAK 2 V 617 F;
Leukaemia 2008; 22: 87-95.
• 12. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK 2 V
617 F to wild- type Jak 2 determines the MPD phenotypes in transgenic
mice. Blood 2008; 111:3931-40.
• 13. Wernig G, Mercher T, Okabe R, et al. Expression of JAK 2 V 617 F
causes a polycythemia vera-like disease with associated myelofibrosis in
a murine bone marrow transplant model. Blood 2006; 107: 4274-81.
• 14. Xing S, Wanting TH, Zhao W, et al. Transgenic expression of JAK
2 V 617 F causes myeloproliferative disorders in mice. Blood 2008;
111: 5109-17.
• 15. Zaleskas VM, Krause DS, Lazarides K, et al. Molecular
pathogenesis and therapy of polycythemia induced in mice by JAK 2 V
617 F. PLOS one 2006; 1: e18.
THANK YOU

More Related Content

What's hot

What's hot (20)

CAR-T Cell Therapy slide share
CAR-T Cell Therapy slide shareCAR-T Cell Therapy slide share
CAR-T Cell Therapy slide share
 
Cytokine and chemokines ppt
Cytokine and chemokines pptCytokine and chemokines ppt
Cytokine and chemokines ppt
 
study of EGFR protein expression and mutation
study of EGFR protein expression and mutation study of EGFR protein expression and mutation
study of EGFR protein expression and mutation
 
Ras presentation complete
Ras presentation completeRas presentation complete
Ras presentation complete
 
Epidermal growth factor and its receptor tyrosine kinase
Epidermal growth factor and its receptor tyrosine kinaseEpidermal growth factor and its receptor tyrosine kinase
Epidermal growth factor and its receptor tyrosine kinase
 
Nf-Kappa B signalling
Nf-Kappa B signalling Nf-Kappa B signalling
Nf-Kappa B signalling
 
Angiogenesis presentation
Angiogenesis presentationAngiogenesis presentation
Angiogenesis presentation
 
Toll like receptors
Toll like receptors   Toll like receptors
Toll like receptors
 
Chapter 3 hallmarks of cancer
Chapter 3 hallmarks of cancerChapter 3 hallmarks of cancer
Chapter 3 hallmarks of cancer
 
JAK STAT SIGNALLING PATHWAY
JAK STAT SIGNALLING PATHWAYJAK STAT SIGNALLING PATHWAY
JAK STAT SIGNALLING PATHWAY
 
Tgfb
TgfbTgfb
Tgfb
 
Targeted therapy anticancer drugs
Targeted therapy anticancer drugsTargeted therapy anticancer drugs
Targeted therapy anticancer drugs
 
Car tcell therapy
Car tcell therapyCar tcell therapy
Car tcell therapy
 
N fk b signaling in cancer
N fk b signaling in cancerN fk b signaling in cancer
N fk b signaling in cancer
 
Hallmarks of cancer
Hallmarks of cancerHallmarks of cancer
Hallmarks of cancer
 
Proto oncogenes
Proto oncogenesProto oncogenes
Proto oncogenes
 
Mapk pathways
Mapk pathwaysMapk pathways
Mapk pathways
 
Targeted cancer therapies
Targeted cancer therapiesTargeted cancer therapies
Targeted cancer therapies
 
JAK-STAT Signalling Pathway
JAK-STAT Signalling PathwayJAK-STAT Signalling Pathway
JAK-STAT Signalling Pathway
 
MAPK -Ras pathway
MAPK -Ras pathwayMAPK -Ras pathway
MAPK -Ras pathway
 

Viewers also liked

Manejo oncológico del cáncer de pulmón
Manejo oncológico del cáncer de pulmónManejo oncológico del cáncer de pulmón
Manejo oncológico del cáncer de pulmónjalmenarez
 
Role of stat3 protein & thelper 17 cell in psoriasis development by yousry
Role  of stat3   protein & thelper 17  cell in psoriasis  development by yousryRole  of stat3   protein & thelper 17  cell in psoriasis  development by yousry
Role of stat3 protein & thelper 17 cell in psoriasis development by yousryM.YOUSRY Abdel-Mawla
 
Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...
Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...
Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...BioMAP® Systems
 
use of omega-transaminase enzyme chemistry in the synthesis of JAK2 kinase in...
use of omega-transaminase enzyme chemistry in the synthesis of JAK2 kinase in...use of omega-transaminase enzyme chemistry in the synthesis of JAK2 kinase in...
use of omega-transaminase enzyme chemistry in the synthesis of JAK2 kinase in...Kashif Haider
 
Selection of Safer and More Effective Anti-inflammatory Kinase Inhibitors usi...
Selection of Safer and More Effective Anti-inflammatory Kinase Inhibitors usi...Selection of Safer and More Effective Anti-inflammatory Kinase Inhibitors usi...
Selection of Safer and More Effective Anti-inflammatory Kinase Inhibitors usi...BioMAP® Systems
 
Ash 2014 update
Ash 2014 updateAsh 2014 update
Ash 2014 updatemadurai
 
Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides coolesanum
 
Crizotinib
CrizotinibCrizotinib
Crizotinib3s4num
 
Stat3 protein in psoriasis by yousry
Stat3 protein in psoriasis  by yousryStat3 protein in psoriasis  by yousry
Stat3 protein in psoriasis by yousryM.YOUSRY Abdel-Mawla
 
01.13.09: Chronic Myeloid Leukemia and other Myeloproliferative Neoplasms (MPNs)
01.13.09: Chronic Myeloid Leukemia and other Myeloproliferative Neoplasms (MPNs)01.13.09: Chronic Myeloid Leukemia and other Myeloproliferative Neoplasms (MPNs)
01.13.09: Chronic Myeloid Leukemia and other Myeloproliferative Neoplasms (MPNs)Open.Michigan
 
Chemo In a Bottle: Oral Chemotherapy for Colorectal Cancer
Chemo In a Bottle: Oral Chemotherapy for Colorectal CancerChemo In a Bottle: Oral Chemotherapy for Colorectal Cancer
Chemo In a Bottle: Oral Chemotherapy for Colorectal CancerFight Colorectal Cancer
 
MCO 2011 - Slide 31 - P. Casali - Spotlight session Sarcoma
MCO 2011 - Slide 31 - P. Casali - Spotlight session SarcomaMCO 2011 - Slide 31 - P. Casali - Spotlight session Sarcoma
MCO 2011 - Slide 31 - P. Casali - Spotlight session SarcomaEuropean School of Oncology
 
Mutations in Chronic myeloid leukaemia and Imatinib resistance
Mutations in Chronic myeloid leukaemia and Imatinib resistanceMutations in Chronic myeloid leukaemia and Imatinib resistance
Mutations in Chronic myeloid leukaemia and Imatinib resistanceDr Sandeep Kumar
 
targeted dds for cancer
targeted dds for cancertargeted dds for cancer
targeted dds for cancerNeha Singh
 
Molecular Genetics in MPN
Molecular Genetics in MPNMolecular Genetics in MPN
Molecular Genetics in MPNARUN KUMAR
 

Viewers also liked (20)

Manejo oncológico del cáncer de pulmón
Manejo oncológico del cáncer de pulmónManejo oncológico del cáncer de pulmón
Manejo oncológico del cáncer de pulmón
 
Stat & psoriasis by yousry
Stat & psoriasis by yousryStat & psoriasis by yousry
Stat & psoriasis by yousry
 
bosutinib
bosutinibbosutinib
bosutinib
 
Role of stat3 protein & thelper 17 cell in psoriasis development by yousry
Role  of stat3   protein & thelper 17  cell in psoriasis  development by yousryRole  of stat3   protein & thelper 17  cell in psoriasis  development by yousry
Role of stat3 protein & thelper 17 cell in psoriasis development by yousry
 
Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...
Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...
Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...
 
use of omega-transaminase enzyme chemistry in the synthesis of JAK2 kinase in...
use of omega-transaminase enzyme chemistry in the synthesis of JAK2 kinase in...use of omega-transaminase enzyme chemistry in the synthesis of JAK2 kinase in...
use of omega-transaminase enzyme chemistry in the synthesis of JAK2 kinase in...
 
Selection of Safer and More Effective Anti-inflammatory Kinase Inhibitors usi...
Selection of Safer and More Effective Anti-inflammatory Kinase Inhibitors usi...Selection of Safer and More Effective Anti-inflammatory Kinase Inhibitors usi...
Selection of Safer and More Effective Anti-inflammatory Kinase Inhibitors usi...
 
Ash 2014 update
Ash 2014 updateAsh 2014 update
Ash 2014 update
 
Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides
 
11 Terapias dirigidas Cáncer de Pulmón
11 Terapias dirigidas Cáncer de Pulmón11 Terapias dirigidas Cáncer de Pulmón
11 Terapias dirigidas Cáncer de Pulmón
 
Crizotinib
CrizotinibCrizotinib
Crizotinib
 
Psoriasis 2014
Psoriasis 2014Psoriasis 2014
Psoriasis 2014
 
Stat3 protein in psoriasis by yousry
Stat3 protein in psoriasis  by yousryStat3 protein in psoriasis  by yousry
Stat3 protein in psoriasis by yousry
 
01.13.09: Chronic Myeloid Leukemia and other Myeloproliferative Neoplasms (MPNs)
01.13.09: Chronic Myeloid Leukemia and other Myeloproliferative Neoplasms (MPNs)01.13.09: Chronic Myeloid Leukemia and other Myeloproliferative Neoplasms (MPNs)
01.13.09: Chronic Myeloid Leukemia and other Myeloproliferative Neoplasms (MPNs)
 
Chemo In a Bottle: Oral Chemotherapy for Colorectal Cancer
Chemo In a Bottle: Oral Chemotherapy for Colorectal CancerChemo In a Bottle: Oral Chemotherapy for Colorectal Cancer
Chemo In a Bottle: Oral Chemotherapy for Colorectal Cancer
 
MCO 2011 - Slide 31 - P. Casali - Spotlight session Sarcoma
MCO 2011 - Slide 31 - P. Casali - Spotlight session SarcomaMCO 2011 - Slide 31 - P. Casali - Spotlight session Sarcoma
MCO 2011 - Slide 31 - P. Casali - Spotlight session Sarcoma
 
Mutations in Chronic myeloid leukaemia and Imatinib resistance
Mutations in Chronic myeloid leukaemia and Imatinib resistanceMutations in Chronic myeloid leukaemia and Imatinib resistance
Mutations in Chronic myeloid leukaemia and Imatinib resistance
 
targeted dds for cancer
targeted dds for cancertargeted dds for cancer
targeted dds for cancer
 
Molecular Genetics in MPN
Molecular Genetics in MPNMolecular Genetics in MPN
Molecular Genetics in MPN
 
Establishing Best Practices for CML Therapy: A Workshop Symposium for the Adv...
Establishing Best Practices for CML Therapy: A Workshop Symposium for the Adv...Establishing Best Practices for CML Therapy: A Workshop Symposium for the Adv...
Establishing Best Practices for CML Therapy: A Workshop Symposium for the Adv...
 

Similar to PRESENTATION ON JANUS KINASE INHIBITORS IN TREATMENT OF MPN'S

Self- Sufficiency in growth signals Cancer..pptx
Self- Sufficiency in growth signals Cancer..pptxSelf- Sufficiency in growth signals Cancer..pptx
Self- Sufficiency in growth signals Cancer..pptxsiddhantkushare
 
Regulation of DNA synthesis
Regulation of DNA synthesis Regulation of DNA synthesis
Regulation of DNA synthesis Omer Yahia
 
Role of jak stat pathway in cancer signalling
Role of jak stat pathway in cancer signallingRole of jak stat pathway in cancer signalling
Role of jak stat pathway in cancer signallingJEYASREEG
 
Cell cycle and molecular basis of cancer.
Cell cycle and molecular basis of cancer.Cell cycle and molecular basis of cancer.
Cell cycle and molecular basis of cancer.Dr Durga Gahlot
 
Mutagenic signal transduction (5)
Mutagenic signal transduction (5)Mutagenic signal transduction (5)
Mutagenic signal transduction (5)Omer Yahia
 
Neoplasia-Molecular basis of cancer
Neoplasia-Molecular basis of cancerNeoplasia-Molecular basis of cancer
Neoplasia-Molecular basis of cancerVaanikaKaira
 
Carcinomagenesis Theories .pdf
Carcinomagenesis Theories .pdfCarcinomagenesis Theories .pdf
Carcinomagenesis Theories .pdfMohitChauhan270470
 
Basics in cancer biology.pdf
Basics in cancer biology.pdfBasics in cancer biology.pdf
Basics in cancer biology.pdfSrimathideviJ
 
Mitochondrial dynamics and cancer (2)
Mitochondrial dynamics and cancer (2)Mitochondrial dynamics and cancer (2)
Mitochondrial dynamics and cancer (2)soumik1997
 
jakstat signaling pathway (Cellular and Molecular Pharmacology)
jakstat signaling pathway (Cellular and Molecular Pharmacology)jakstat signaling pathway (Cellular and Molecular Pharmacology)
jakstat signaling pathway (Cellular and Molecular Pharmacology)PurvaVernekar
 
Therapeutic strategies that target the cellular transformation process for ca...
Therapeutic strategies that target the cellular transformation process for ca...Therapeutic strategies that target the cellular transformation process for ca...
Therapeutic strategies that target the cellular transformation process for ca...JiaYiiChong
 
Kinase inhibitors in cancer treatment.pptx
Kinase inhibitors in cancer treatment.pptxKinase inhibitors in cancer treatment.pptx
Kinase inhibitors in cancer treatment.pptxHome
 

Similar to PRESENTATION ON JANUS KINASE INHIBITORS IN TREATMENT OF MPN'S (20)

Self- Sufficiency in growth signals Cancer..pptx
Self- Sufficiency in growth signals Cancer..pptxSelf- Sufficiency in growth signals Cancer..pptx
Self- Sufficiency in growth signals Cancer..pptx
 
Regulation of DNA synthesis
Regulation of DNA synthesis Regulation of DNA synthesis
Regulation of DNA synthesis
 
Role of jak stat pathway in cancer signalling
Role of jak stat pathway in cancer signallingRole of jak stat pathway in cancer signalling
Role of jak stat pathway in cancer signalling
 
Mieloproliferativo
MieloproliferativoMieloproliferativo
Mieloproliferativo
 
Cell cycle and molecular basis of cancer.
Cell cycle and molecular basis of cancer.Cell cycle and molecular basis of cancer.
Cell cycle and molecular basis of cancer.
 
Cancer genes
Cancer genesCancer genes
Cancer genes
 
Mutagenic signal transduction (5)
Mutagenic signal transduction (5)Mutagenic signal transduction (5)
Mutagenic signal transduction (5)
 
HALLMARKS OF CANCER
HALLMARKS OF CANCERHALLMARKS OF CANCER
HALLMARKS OF CANCER
 
Neoplasia-Molecular basis of cancer
Neoplasia-Molecular basis of cancerNeoplasia-Molecular basis of cancer
Neoplasia-Molecular basis of cancer
 
Hallmarks of cancer
Hallmarks of cancerHallmarks of cancer
Hallmarks of cancer
 
Carcinogenesis
CarcinogenesisCarcinogenesis
Carcinogenesis
 
Carcinomagenesis Theories .pdf
Carcinomagenesis Theories .pdfCarcinomagenesis Theories .pdf
Carcinomagenesis Theories .pdf
 
Oncogenes
OncogenesOncogenes
Oncogenes
 
Basics in cancer biology.pdf
Basics in cancer biology.pdfBasics in cancer biology.pdf
Basics in cancer biology.pdf
 
Anti neoplastic agents
Anti neoplastic agentsAnti neoplastic agents
Anti neoplastic agents
 
Mitochondrial dynamics and cancer (2)
Mitochondrial dynamics and cancer (2)Mitochondrial dynamics and cancer (2)
Mitochondrial dynamics and cancer (2)
 
jakstat signaling pathway (Cellular and Molecular Pharmacology)
jakstat signaling pathway (Cellular and Molecular Pharmacology)jakstat signaling pathway (Cellular and Molecular Pharmacology)
jakstat signaling pathway (Cellular and Molecular Pharmacology)
 
Therapeutic strategies that target the cellular transformation process for ca...
Therapeutic strategies that target the cellular transformation process for ca...Therapeutic strategies that target the cellular transformation process for ca...
Therapeutic strategies that target the cellular transformation process for ca...
 
Kinase inhibitors in cancer treatment.pptx
Kinase inhibitors in cancer treatment.pptxKinase inhibitors in cancer treatment.pptx
Kinase inhibitors in cancer treatment.pptx
 
Multistep Carcinogenesis
Multistep CarcinogenesisMultistep Carcinogenesis
Multistep Carcinogenesis
 

Recently uploaded

Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...GENUINE ESCORT AGENCY
 
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...mahaiklolahd
 
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...khalifaescort01
 
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service AvailableDipal Arora
 
Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...
Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...
Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...adilkhan87451
 
Call Girls Madurai Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Madurai Just Call 9630942363 Top Class Call Girl Service AvailableCall Girls Madurai Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Madurai Just Call 9630942363 Top Class Call Girl Service AvailableGENUINE ESCORT AGENCY
 
Most Beautiful Call Girl in Bangalore Contact on Whatsapp
Most Beautiful Call Girl in Bangalore Contact on WhatsappMost Beautiful Call Girl in Bangalore Contact on Whatsapp
Most Beautiful Call Girl in Bangalore Contact on WhatsappInaaya Sharma
 
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...chetankumar9855
 
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service AvailableCall Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service AvailableGENUINE ESCORT AGENCY
 
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...karishmasinghjnh
 
Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...
Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...
Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...Anamika Rawat
 
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...vidya singh
 
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In AhmedabadGENUINE ESCORT AGENCY
 
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...parulsinha
 
Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...
Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...
Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...Sheetaleventcompany
 
Call Girls Rishikesh Just Call 9667172968 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 9667172968 Top Class Call Girl Service AvailableCall Girls Rishikesh Just Call 9667172968 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 9667172968 Top Class Call Girl Service Availableperfect solution
 
Call Girls Ahmedabad Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Ahmedabad Just Call 9630942363 Top Class Call Girl Service AvailableCall Girls Ahmedabad Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Ahmedabad Just Call 9630942363 Top Class Call Girl Service AvailableGENUINE ESCORT AGENCY
 
Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...
Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...
Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...hotbabesbook
 
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any TimeTop Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any TimeCall Girls Delhi
 
Call Girls Service Jaipur {8445551418} ❤️VVIP BHAWNA Call Girl in Jaipur Raja...
Call Girls Service Jaipur {8445551418} ❤️VVIP BHAWNA Call Girl in Jaipur Raja...Call Girls Service Jaipur {8445551418} ❤️VVIP BHAWNA Call Girl in Jaipur Raja...
Call Girls Service Jaipur {8445551418} ❤️VVIP BHAWNA Call Girl in Jaipur Raja...parulsinha
 

Recently uploaded (20)

Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
 
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
 
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
 
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
 
Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...
Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...
Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...
 
Call Girls Madurai Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Madurai Just Call 9630942363 Top Class Call Girl Service AvailableCall Girls Madurai Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Madurai Just Call 9630942363 Top Class Call Girl Service Available
 
Most Beautiful Call Girl in Bangalore Contact on Whatsapp
Most Beautiful Call Girl in Bangalore Contact on WhatsappMost Beautiful Call Girl in Bangalore Contact on Whatsapp
Most Beautiful Call Girl in Bangalore Contact on Whatsapp
 
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
 
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service AvailableCall Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
 
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...
 
Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...
Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...
Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...
 
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
 
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
 
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
 
Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...
Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...
Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...
 
Call Girls Rishikesh Just Call 9667172968 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 9667172968 Top Class Call Girl Service AvailableCall Girls Rishikesh Just Call 9667172968 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 9667172968 Top Class Call Girl Service Available
 
Call Girls Ahmedabad Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Ahmedabad Just Call 9630942363 Top Class Call Girl Service AvailableCall Girls Ahmedabad Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Ahmedabad Just Call 9630942363 Top Class Call Girl Service Available
 
Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...
Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...
Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...
 
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any TimeTop Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
 
Call Girls Service Jaipur {8445551418} ❤️VVIP BHAWNA Call Girl in Jaipur Raja...
Call Girls Service Jaipur {8445551418} ❤️VVIP BHAWNA Call Girl in Jaipur Raja...Call Girls Service Jaipur {8445551418} ❤️VVIP BHAWNA Call Girl in Jaipur Raja...
Call Girls Service Jaipur {8445551418} ❤️VVIP BHAWNA Call Girl in Jaipur Raja...
 

PRESENTATION ON JANUS KINASE INHIBITORS IN TREATMENT OF MPN'S

  • 1. ARE JAK 2 INHIBITORS THE SOLUTION FOR TREATMENT OF MYELOPROLIFERATIVE DISEASES
  • 2. DONE BY: TAMMALI HARIKA (09Z31R0020) AINALA SRAVANI REDDY (09Z31R0024) KUTHADI PRIYANKA (09Z31R0042) MAILARAPU NAVYA (09Z31R0045) MUTHYAM ROJA RANI (09Z31R0046) SAFURA AYESHA MUJEEB (09Z31R0054) UNDER THE GUIDANCE OF MRS . SIVA JYOTHI BUGGANA, M. PHARMACY MEDICINAL CHEMISTRY
  • 3. CONTENTS. • Abstract • Introduction to cancer • Targets of Cancer • Plan of work • Introduction to Janus Kinases (JAK) • Introduction to STAT • Coordination between JAK and STAT • Scaffolds used to synthesize JAK2 inhibitors • JAK2 inhibitors under clinical phases • Conclusion • Bibliography
  • 4. • ABSTRACT: • Janus kinases (JAKS) are critical components of cytokine signaling pathways which regulate immunity, inflammation, haematopoiesis, growth and development. • The recent discovery of JAK2- activating mutations as a casual event in majority of patients with Philadelphia chromosomes negative (ph- )myeloproliferative disorders (MPDS) promoted many pharmaceutical companies to develop JAK2 selective inhibitors for the treatment of MPD’S
  • 5. • JAK2 inhibitors effectively reduce JAK2 driver phosphorylation of signal – transducer and activator of transcription 5, and cell survival in JAK 2 activated cells in vitro and invivo. • Patients treated with these inhibitors experience a rapid reduction of splenomegaly, significant improvement of constitutional symptoms.
  • 6. INTRODUCTION: • Cancer is a disease in which there is uncontrolled multiplication and spread within the body of abnormal forms of the body’s own cells. • They are distinguished from benign tumours by the properties of dedifferentiation, invasiveness and the ability to metastasise (spread to other parts of the body) both benign and malignant tumours manifest uncontrolled proliferation.
  • 7. • PATHOGENISIS OF CANCER:- • Cancer cell distinguish from normal cell by :- • 1. Uncontrolled proliferation • 2. Dedifferentiation • 3. Invasiveness • 4. Metastasis.
  • 8. APOPTOSIS • Apoptosis is programmed cell death . Development of resistance to apoptosis is hallmark of cancer. The decrease of apoptosis can be brought about inactivation of proapoptotic factors or by activation of antiapoptotic factors
  • 9. GENESIS OF A CANCER CELL:- A normal cell turns into a cancer cell because of one or more mutations in its DNA which can be inherited or acquired. There are two main categories of genetic change that lead to cancer they are : 1)Activation of proto oncogenes to oncogenes . 2)Inactivation of tumour suppressor genes. Eg: breast cancer.
  • 10. CELL CYCLE:- The normal cell proliferate throught a definite cell cycle that causes programme DNA replications. The mechanism of cell division is same in all dividing phase and is divided into 5 phases. They are: 1. Go(Gap o (or) Resting (or) non-Proliferative phase) 2. Phase G1 3. S Phase 4. G2 Phase 5. M-Phase
  • 11.
  • 12. NEGATIVE REGULATORS OF CELL CYCLE:- • Rb protein that holds the cycle in check while it is hypophosphorylated another negative regulatory mechanism is the action of the inhibitors of the cdk’s. • These bind to and inhibits the action of the complexes, their main actions being at check point 1. THERE ARE 2 FAMILIES OF INHIBITORS:- 1) Kinase inhibitory protein family (cdk inhibitory proteins, also termed KIP/kinanes inhibitory proteins:P21,P27 and P53. 2) Inhibitors of kinase family (INK FAMILY):- P16, P19, P15.
  • 13. TARGET SITES • A) CONVENTIONAL OR TRADITIONAL TARGETS: • These include alkylating agents, anti metabolites, antibiotics, plant alkaloids, radio isotopes. • B) NEXT GENERATION TARGETS: • 1. Cell signaling pathway • 2. Protein therapy • 3. Protein- protein interaction • Cancer related genes as targets: • These genes are of 2 types they are: • a)oncogenes. b) Tumour suppressor gene.
  • 14.
  • 15. 1.Oncogenes: oncogenes contribute to the transformation process by driving cell proliferation or reducing sensitivity to cell death. Classes of oncogenes- a)Growth factors: GF’S are produced by one cell and they act on other cells this is known as paracrine stimulation. Cancer cell secrete their own GF’S and they proliferate to form tumours this is known as autocrine stimulation. b)Growth factor receptors c)Membrane associated guanine nucleotide binding protein. d)Serine threonine protein kinases. e)Cytoplasmic proteins. f)Cytoplasmic tyrosine kinases.
  • 16. 2.Tumour suppressor genes: These genes can directly or indirectly inhibit cell growth. Direct inhibitors promote cell death and are called `gate keepers’ and their activating is rate limiting for tumor cell proliferation. Indirect inhibitors promote genetic stability and are called `care takers’ which function in DNA repair pathways and whose elimination causes increased initiation rate. a)Retinoblastoma : Loss of Rb protein function leads to malignancy. It may be either phosphorylated or unphosphorylated. b)p53: it is activated in respose to cellular stresses created by activated oncogenes.
  • 17.
  • 18. Biochemical targets: a)Reactive oxygen species- Ionizing radiation is the complete carcinogen and causes DNA damage. b)Matrix metalloproteinases -They play an integral role in malignant progression. c)Telomerase expression-Telomers are specialised structures that cap the ends of chromosomes (like small metal tubes on the end of shoe lace) protection them from the degradation, rearrangement and fusion with other chromosomes. A portion of telomere is eroded with each round of cell division so that eventually it becomes non functional
  • 19. PLAN OF WORK • Till now anticancer drugs available in the market are almost having same mechanism of action, that is damaging the DNA synthesis in affected cells and also damaging the normal cells along with the neoplastic cells. • Now we are trying to collect the information regarding the treatment of cancer by using future generation targets, one of that is Janus kinase inhibitors. Here we are ready to present the information regarding Janus kinases.
  • 20. INTRODUCTION:-  JAK2V617F was the first mutation to be described in patients with ph- negative MPN’S and the fact that it can be detected in patients with all 3 classic subtypes of MPN’s.  After discovery of JAK2V617F;other investigators discovered mutation in related genes of hemopoietic growth factor signaling pathways,including exon 12 mutations in JAK2,Mutation of MPL.
  • 21. THE JAK FAMILY OF TYROSINE KINASE: • The JAK family of tyrosine kinase (named after the two faced roman god janus) was first described in 1989. • There are four members of the JAK family ; JAK1,JAK2,JAK3 and TYK. • JAKs are cytoplasmic kinases that associate with the intracellular portion of cytokine receptors that do not posses intrinsic kinase activity ,such as receptors for hematopoietic growth factors (erythropoietin receptor [EPOR] ,G-CSF receptor [G-CSFR] ,and thrombopoietin receptor [C-MPL] • Binding of the putative ligand leads to receptor dimerization and subsequent approximation of two JAK kinases ,which transphosphorylates and activate each other, initiating intracellular signalling pathways
  • 22.
  • 23. • One of the most important intracellular signalling pathways activated by JAKs is the JAK-STAT(signal transducer and activator of transcription) pathway. • STAT are latent,cytoplasmic transcription factors. JAKS phosphorylate STATs tyrosine residues; leading to STAT dimerization , translocation to the nucleus and activation of transcription. • Aberrant activation of STAT3 and STAT5 has been linked to neoplastic transformation.
  • 24. • Other signalling pathways which can be activated by ;JAKs include the Ras/Raf/MAPK pathway and the PBK/Akt pathway. Activation of these pathways leads to increased cellular proliferation and resistance to apoptosis , and deregulation could cause the development hematological malignancies. • Structurally,JAKs consists of seven different domains
  • 25. THE JAK 2 V617F MUTATION:- • It was identified primarily in patients with PV (90-97%), ET (60%) and PMF (50%). • It was identified primarily in patients with PV (90-97%), ET (60%) and PMF (50%). • In PV > 75% allelic burden is associated with higher hematocrit, white blood cell (WBC) count, and higher incidence splenomegaly and thrombotic events. Patients with primary MF who are JAk 2 V617F – positive may have higher haemoglobin & WBC count and a higher risk of leukemic transformation & of developing massive splenomegaly . V617F appears to promote a polycythaemic phenotype in patients with both ET & IMF
  • 26. • The patients with V617F – negative MPNS led to the discovery of other mutation JAk 2 exon 12 mutation in 3% of pv patients. • These mutations also lead to increased cellular proliferation and hyper sensitivity or independency to hematopoietic growth factors indeed, JAK 2 V617F negative erythroid colonies from patients with PV can grow in the absence of erythropoietin. RATIONALE FOR TARGETING JAK 2 IN MPN’S : • Imatinib, These drugs target kinases that are abnormally activated in cancer cells, with the objective of blocking cellular proliferation and inducing apoptosis .
  • 27. There is great therapeutic benefit for employing these drugs to achieve symptom control and improve the quality of life of patient with MPNS
  • 28. SCAFFOLDS USED AS JAK-2 INHIBITORS: QUINAZOLINES 2,4-diamino triazole. QUINOXALINES 3,4-ring fused 7- azaindoles
  • 30. JAK2 INHIBITORS UNDER CLINICAL TRIALS 1. CEP-701: It is also known as a lestaurtinib is a TK1 which belongs to the chemical class of indocarbazol of alkaloid. It is a potent FLT3 and JAK2 inhibitor. • DOSE: 80-100mg twice daily as a liquid formulation. • USES:  Reduction in spleen size with improvement in cytopenias.  Use to treat patients with JAK2V617F-positive primary MF (or) post PV/ET MF and clinical . • ADRS: * Myelosuppression. *GI toxicity
  • 31. 2. AZD1480: it is a pyrazolyl pyrimidine compound that selectively and potently inhibits JAK2. • MOA: This compound block STAT 5 activation, inhibit the cell proliferation and induced apoptosis in the human JAK2V617F positive. • In a mouse model, AZD-1480 reduced the proliferation of stem cells transferred with the JAK2 mutant protein. • USES:  Therapy with AZD 1480 inhibited tumour growth, and tumour cells lysates had reduced level phospho STAT3.  A phase 1 clinical trail is currently underway to evaluate the activity of AZD1480 in patients with MPNS.
  • 32. 3.R723: This compound is strongly antiproliferative against mouse and human cell lines that harvor the JAK2V617F mutation , constitutive STAT5 phosphorylation in JAK2V617F positive cells was inhibited 10-20 fold more potently than IL-2 induced STAT5 phosphorylation 4. XL019: It is a potent , reversible and selective inhibitor of both wild type and mutated JAK2 and shows good selectivity for JAK2 invitro biochemical assays.
  • 33. DOSE: Given orally once daily or three times weekly. Tolerated dose is 25 and 50mg/kg. ADRS: * Non-haematological adverse effects. * Leukocynosis, decrease of circulating blasts, improvement of anaemias, pruritis and poor appetite.
  • 34. 5. INCB018424: It is a potent pan JAK inhibitor targeting JAK1, JAK2,and TYK2. • MOA:INCB018424 Inhibits constitutive and IL-6 stimulated phosphorylation of STAT3 and reduces production of proinflammatory cytokines in all MF patients regardless of their JAK2 mutation status. • DOSE: The starting dose of 25mg pobid was demonstrated to be maximum tolerated dose. • USES:  Therapy with INCB018424 also improved hyper catabolism-associated hypocholestrolemia.  INCB018424 treatment also resulted in a rapid reduction of spleenomegaly.
  • 35. INCB-18424 • 6. SB1518: It is a JAK2 inhibitor that has activity against both wild type and mutated JAK2,being selective against JAK1 and JAK3. • MOA: SB1518 INHIBITS PROLIFERATION OF Baf/3 cells transferred with the erythropoietin receptor (EPOR) and the JAK2 V617F mutation and decreased phosphorylation of JAK2 and STAT5.
  • 36. • DOSE: Ranged from 100- 600mg orally once daily in 28-days cycles. • ADRS:  Abdominal pain and diarrhea.  Nausea and thrombocytopenia. 7. TG101348:It is an orally available, potent JAK2 inhibitor with greater selectivity against JAK1 and JAK3.
  • 37. . USES: • TG101348 is able to induce response in splenomegaly in the majority of patient with MF and this may be due to a direct effect on inhibition of JAK2V612F. • MOA:TG101348 inhibited proliferation and induce apoptosis of JAK2 V617F positive HEL cells and Ba/f3 cells transduced with JAK V617F. Dose: TG101348 was well tolerated in patience with MF when the drug was taken orally once a day. ADRS: Non hematological toxicities. Thrombocytopenia, neutropenia, Tronuition depended anaemia.
  • 38. • TG101348 also led to improvement in system is symptoms, including pruritis, night sweats, fatigue • 8. CYT387:It is a amino pyrimidine compound is an ATP competitive small molecules that potently inhibits JAK1 and JAK2 . CYT387 also inhibits JAK3 but to a lesser extent. MOA:CYT387 inhibits proliferation of cell lines that depend on signaling by JAK kinases for proliferation, including Ba/f3 cells engineered to express both EPOR and JAK2 V617F .
  • 39. • USES:  Therapy with CYT387 in mice developed with the splenomegaly , erythrocytosis , leukocytosis , splenomegaly and bone marrow fibrosis improved hemoglobin levels , normalized WBC counts and reduced spleen size.  A reduction but not elimination of JAK2 disease burden , with partial normalization of progenitor cell distribution and differentiation by this compound was also observed in the model.
  • 40. • DRUGS UNDER CLINICAL TRIALS • DRUG CURRENT PHASE CEP701 ‫װ/׀‬ AZD1480 ‫׀‬ R723 Pre-clinical XL019 ‫׀‬ INCB18424 ‫׀׀׀‬ SB1518 ‫׀‬ TG101348 ‫װ‬ CYT387 ‫׀‬
  • 41. Conclusion • Jak 2 inhibitors are a new class of drugs being actively developed for patients with ph negative MPNs they are the solution to all clinical issues in patients with MPNs, great clinical benefit can be obtained by the use of these drugs. • In patients with MF, therapy JAK2 inhibitors can lead to improvement in spleen size, WBC count weight loss, fatigue, night sweats and is associated with improved quality of life.
  • 42. BIBILOGRAPHY:- 1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine Kinase JAK 2 in human myeloproliferative disorders, Lancet 2005; 365: 1054-61. 2. James C; Ugo V, Le Couedic JP et al. A unique clonal JAK 2 mutation leading to constitutive Signaling causes polycythaemia Vera, Nature 2005; 434: 1144-8. 3. Kralovics R, passamonti F, Buser AS, et al; A gain of function mutation of JAK 2 in myeloproliferative disorders N Engl Med 2005; 352: 1779-90. 4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK 2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis, Cancer cell, 2005; 7: 387-97.
  • 43. • 5. Akada H, Yan D, Zou H, et al. conditional expression of heterozygous (or) homozygous JAK 2 V 617 F from its endogenous promoter induces a polycythemia Vera like disease Blood 2010; 115: 3589-97.6. Bumm TG; Elsea C, • 6. Bumm TG; Elsea C, Corbin AS, et al. characterization of murine JAK 2 V 617F-positive myeloproliferative disease Cancer Res 2006; 66: 11156-65. • 7. Lacout C, pisani DF, Tulliez M, et al. JAK 2 V 617 F expression in murine hematopoietic cells leads to MPD mimicking human pv with secondary myelofibrosis, blood 2006; 108: 1652-60. • 8. LiJ, Spensberger D, Ahn JS, et al, JAK 2 V 617 F impairs hematopoietic stem cell function in a conditional Knock-in mouse model of JAK 2 V 617 F-positive essential thrombocythemia, Blood 2010; 116: 1528-38.
  • 44. • 9. Marty C, Lacout C, Martin A, et al. myeloproliferative neoplasm induced by constitutive expression of JAK 2 V 617 F in Knock-in mice, Blood 2010; 116; 783-7. • 10. Mullally A, Lane SW, Ball B, et al. physiological JAK 2 V 617 F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer cell 2010; 17:584-96. • 11. Shide K; Shimoda HK; Kumano T, et al. Development of ET, primary myelofibrosis and pv in mice expressing JAK 2 V 617 F; Leukaemia 2008; 22: 87-95.
  • 45. • 12. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK 2 V 617 F to wild- type Jak 2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111:3931-40. • 13. Wernig G, Mercher T, Okabe R, et al. Expression of JAK 2 V 617 F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274-81. • 14. Xing S, Wanting TH, Zhao W, et al. Transgenic expression of JAK 2 V 617 F causes myeloproliferative disorders in mice. Blood 2008; 111: 5109-17. • 15. Zaleskas VM, Krause DS, Lazarides K, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK 2 V 617 F. PLOS one 2006; 1: e18.